Biotech Startups

OpenProtein.AI (ne47.bio) develops protein language and generative AI models for end-to-end protein engineering, including de novo sequence design, variant effect prediction, in silico library screening, and training of specialized models on proprietary data. Its tools are offered to biology and computational research teams through a no-code GUI and programmatic APIs to accelerate design-build-test cycles.

1 investor

Nebuflow develops drug delivery technology for pharmaceutical applications. The company focuses on transforming how life-changing drugs are delivered.

1 investor

Nectero Therapeutics develops therapeutic medical devices with a focus on vascular medicine applications. The company is led by a team with extensive experience in regulatory affairs, product development, and quality assurance for medical device manufacturing.

1 investor

Palomar Labs (formerly Negev Labs) is a venture studio that rediscovers overlooked drugs with prior human exposure, secures new IP around better indications or formulations, and builds a company around each asset, focused on late-life neuropsychiatric disease. Its programs include investigational therapies for apathy in Parkinson's disease, late-life depression, and agitation/aggression in neurodegeneration.

1 investor

MyHealthChecked provides personalized health testing infrastructure and wellness management services designed to help individuals understand their personal health priorities and make sustainable lifestyle improvements.

1 investor

NemaGen Discoveries develops first-in-class therapies targeting mast cell-related diseases and chronic inflammation by leveraging insights from studying the body's natural inflammatory response to parasitic infections.

1 investor

1 investor

Neo-Bionica develops neurotechnology devices and systems, leveraging expertise in implantable device design, neural interfaces, and medical device engineering for the neurotech market.

1 investor

Neobiomics develops multi-strain food supplements rooted in academic research, with collaborations across Europe. The company is affiliated with Karolinska Institutet and focuses on bringing innovative, science-based nutritional products to market.

1 investor

NeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.

1 investor

Neoindicate develops biomarkers and agents that target tumor microenvironments for cancer diagnosis, imaging, and treatment across multiple cancer types including brain tumors, melanoma, and breast cancer.

1 investor

Neopharm is a South Korean cosmetics and skincare company that develops proprietary ingredients and products, including scalp-care shampoos and dermatological skincare items. It is a publicly listed company (ticker: 네오팜) offering consumer beauty and skin health products.

1 investor

Neoplants is a plant engineering company working to expand the capabilities of plants. The site is a pre-launch teaser with limited detail about specific products.

1 investor

Neoplants is a plant engineering company working to unlock the biological potential of plants. The site is a pre-launch teaser with minimal detail on specific products.

1 investor

1 investor

Neotis develops immunotherapies to counteract age-related tissue decline by directing the immune system, with an initial focus on fibrotic disease. The company combines expertise in immunology, senescence, and biomarker development.

1 investor

NeoVac develops proprietary lipid technology for lipid nanoparticles (LNPs) designed to support mRNA-based therapeutics in vaccines, cancer immunotherapy, and autoimmune disease treatment. The company's lipid platform emphasizes tunable degradability to enhance safety and efficacy profiles.

1 investor

Nephrodi is a biotechnology company developing treatments for kidney conditions, including the rare disease Nephrogenic Diabetes Insipidus (NDI). Its work centers on renal physiology research and translating it toward clinical products.

1 investor

Nerai is a biotechnology company developing personalized CRISPR-based genome editors through its MORPHEME platform, which combines automated directed evolution, high-throughput functional screening, and machine learning. It focuses on one-time genetic therapies for rare inherited diseases, with initial programs targeting the liver and retina.

1 investor

Phosphatase-focused immunotherapy drug discovery company; acquired by Boehringer-Ingelheim for up to $1.3B in 2024.

1 investor

NervMyo Therapeutics develops a long-acting injectable delivery system combining a FDA-approved biologic (IGF-1) to improve nerve regrowth and prevent muscle wasting following peripheral nerve injury. The company targets nerve injury patients requiring regenerative therapeutics.

1 investor

Net-Targets applies AI-enhanced systems biology to identify drug targets and mechanisms for pharmaceutical development. The company combines biological experimentation, mathematical modeling, and computer simulation to uncover hidden biological networks that inform medicine development.

1 investor

NE Tech uses patented extraction technology developed at the University of Canterbury to produce high-purity active ingredients for the dietary supplement industry. Its room-temperature process aims to lower cost and waste while improving taste of the extracts.

1 investor

Neucore Bio develops precision therapeutics using engineered exosomes derived from fibroblasts to deliver molecular-level cellular repair and renewal across genetic and degenerative diseases with high unmet medical needs.

1 investor